MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

33.58 -6.64

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.46

Massimo

35.99

Metriche Chiave

By Trading Economics

Entrata

33M

-48M

Vendite

-2.6M

106M

Margine di Profitto

-45.487

Dipendenti

1,869

EBITDA

19M

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+61.18% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

475M

3.9B

Apertura precedente

40.22

Chiusura precedente

33.58

Notizie sul Sentiment di mercato

By Acuity

50%

50%

169 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lug 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lug 2025, 21:04 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lug 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lug 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:30 UTC

Discorsi di Mercato
Utili

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lug 2025, 22:04 UTC

Discorsi di Mercato
Utili

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lug 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lug 2025, 21:58 UTC

Discorsi di Mercato
Utili

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lug 2025, 21:57 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:47 UTC

Utili

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lug 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lug 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 21:05 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lug 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

61.18% in crescita

Previsioni per 12 mesi

Media 58.04 USD  61.18%

Alto 75 USD

Basso 38.2 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

169 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.